In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The project will leverage Noetik's AI model and multimodal spatial data to search for biomarkers of patient response to Agenus' immunotherapy regimen.

NEW YORK – Abbisko Therapeutics on Monday said it dosed the first patient with FGF19-overexpressing liver cancer in a registrational study to establish the safety and efficacy of its FGFR4 inhibitor ...

NEW YORK – Myrio, an Australian T-cell therapy developer, will soon begin testing its PHOX2B PC-CAR T-cell therapy in neuroblastoma patients in a Phase I clinical trial, the company announced Monday.

The firm will stop shipping the gene therapy for these patients until a new immunosuppressive regimen is approved for managing acute liver failure.

The drug is already approved for KMT2A-rearranged AML, and Syndax is hoping for approval in NPM1-mutated disease by the end of the year.

The company plans to use some of the funds to support development of a kinase inhibitor in Phase I testing for BCR-ABL fusion-positive chronic myeloid leukemia.